Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM CD versus COVERA HS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM CD versus COVERA HS.
CARDIZEM CD vs COVERA-HS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in dilation of coronary arteries and peripheral arterioles, and decreased myocardial contractility and conduction velocity.
Verapamil hydrochloride is a phenylalkylamine calcium channel blocker that inhibits calcium ion influx across cardiac and smooth muscle cells, thereby reducing afterload and myocardial contractility. In the heart, it slows atrioventricular conduction and prolongs the effective refractory period; in vascular smooth muscle, it causes vasodilation, reducing peripheral vascular resistance.
Hypertension: 180-360 mg once daily orally. Angina: 120-360 mg once daily orally. Maximum dose: 480 mg/day.
180 mg orally once daily at bedtime, extended-release tablet. Maximum dose 540 mg/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (single dose), prolonged to 10-15 hours with multiple dosing or in elderly/hepatic impairment. Clinical context: Therapeutic steady-state achieved in 2-4 days.
Terminal elimination half-life is 6–17 hours for immediate-release; for Covera-HS (controlled-onset extended-release), the half-life is 10–20 hours, allowing once-daily bedtime dosing to achieve peak effect in the morning.
Renal: ~2-4% (unchanged), Hepatic metabolism to multiple metabolites; ~65% renal (metabolites), ~35% fecal/biliary. Total clearance: 5-7 mL/kg/min.
Primarily hepatic metabolism (oxidation and glucuronidation) with renal excretion of inactive metabolites; approximately 80% of metabolites are excreted renally and 15% fecally.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker